Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biontech Se ADR (BNTX)

Biontech Se ADR (BNTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 21,617,472
  • Shares Outstanding, K 225,182
  • Annual Sales, $ 2,977 M
  • Annual Income, $ -719,920 K
  • EBIT $ -1,029 M
  • EBITDA $ -706 M
  • 60-Month Beta 1.30
  • Price/Sales 7.32
  • Price/Cash Flow N/A
  • Price/Book 1.00

Options Overview Details

View History
  • Implied Volatility 42.10% (-0.01%)
  • Historical Volatility 36.97%
  • IV Percentile 34%
  • IV Rank 20.34%
  • IV High 70.47% on 04/08/25
  • IV Low 34.86% on 07/09/25
  • Expected Move (DTE 14) 6.03 (6.28%)
  • Put/Call Vol Ratio 1.16
  • Today's Volume 961
  • Volume Avg (30-Day) 1,149
  • Put/Call OI Ratio 0.85
  • Today's Open Interest 43,927
  • Open Int (30-Day) 46,032
  • Expected Range 89.97 to 102.03

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.57
  • Number of Estimates 6
  • High Estimate 0.32
  • Low Estimate -1.46
  • Prior Year 1.15
  • Growth Rate Est. (year over year) -149.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
94.00 +2.13%
on 11/24/25
113.39 -15.34%
on 11/12/25
-8.83 (-8.42%)
since 11/04/25
3-Month
90.12 +6.52%
on 09/12/25
114.89 -16.44%
on 09/05/25
-7.50 (-7.25%)
since 09/04/25
52-Week
81.20 +18.23%
on 04/07/25
129.27 -25.74%
on 01/07/25
-18.70 (-16.30%)
since 12/04/24

Most Recent Stories

More News
Pfizer Is Giving Up on BioNTech. Should You Ditch BNTX Stock Now Too?

Pfizer is looking to sell its remaining stake in Covid-19 vaccine partner BioNTech. Have the good days finally come to an end?

PFE : 25.70 (+0.51%)
BNTX : 96.00 (-0.75%)
BMY : 51.95 (+1.94%)
Citi Keeps Their Buy Rating on BioNTech SE (BNTX)

In a report released today, Geoff Meacham from Citi maintained a Buy rating on BioNTech SE. The company’s shares opened today at $101.91.Elevate Your Investing Strategy: Take advantage of TipRanks Premium...

BNTX : 96.00 (-0.75%)
TD Cowen Sticks to Their Hold Rating for BioNTech SE (BNTX)

TD Cowen analyst Yaron Werber maintained a Hold rating on BioNTech SE today and set a price target of $120.00. The company’s shares closed yesterday at $102.21.Elevate Your Investing Strategy: Take advantage...

BNTX : 96.00 (-0.75%)
BMO Capital Releases a Buy Rating on BioNTech SE (BNTX)

In a report released on September 30, Evan Seigerman from BMO Capital assigned a Buy rating to BioNTech SE, with a price target of $143.00. The company’s shares closed yesterday at $102.21.Elevate Your...

BNTX : 96.00 (-0.75%)
Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TEM),(NASDAQ:CRSP),(NASDAQ:BNTX),(NYSE:BMY) EQNX::TICKER_END

AVAI : 0.2951 (-1.63%)
CRSP : 58.18 (+3.91%)
TEM : 76.33 (+1.90%)
BNTX : 96.00 (-0.75%)
BMY : 51.95 (+1.94%)
Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises

MarketNewsUpdates News Commentary

CRSP : 58.18 (+3.91%)
AVAI : 0.2951 (-1.63%)
TEM : 76.33 (+1.90%)
BNTX : 96.00 (-0.75%)
BMY : 51.95 (+1.94%)
Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises

/CNW/ -- Cell therapy refers to a treatment that involves the use of living cells to treat diseases. The cell therapy market has been experiencing significant...

AVAI : 0.2951 (-1.63%)
CRSP : 58.18 (+3.91%)
TEM : 76.33 (+1.90%)
BNTX : 96.00 (-0.75%)
BMY : 51.95 (+1.94%)
Stocks Set to Open Higher as Investors Await Fed Meeting and U.S. Economic Data

September S&P 500 E-Mini futures (ESU25) are up +0.19%, and September Nasdaq 100 E-Mini futures (NQU25) are up +0.08% this morning, pointing to a slightly higher open on Wall Street amid optimism ahead...

NVDA : 183.38 (+2.11%)
ANET : 128.55 (+0.59%)
NQU25 : 24,568.07s (+0.44%)
ADI : 277.26 (-0.35%)
BLDR : 111.01 (-3.00%)
TXN : 180.12 (-1.36%)
BNTX : 96.00 (-0.75%)
RUI.FP : 32.420 (+0.81%)
GIS : 45.98 (-0.48%)
TSLA : 454.53 (+1.74%)
LEN : 126.75 (-4.79%)
RH : 159.94 (-1.46%)
FDA Accelerates Cancer Drug Pipeline as Market Momentum Surges Past $400B

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The FDA's unprecedented accelerated approval pace through August 2025 has delivered breakthrough treatments...

ONCY : 0.9807 (+8.19%)
IOVA : 2.20 (-0.45%)
OLMA : 27.64 (+1.43%)
ALXO : 1.3700 (+3.79%)
BNTX : 96.00 (-0.75%)
Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula

Phase 3 clinical trial cohort of adults 65+ and 18-64 with at least one underlying risk condition shows at least a 4-fold increase in LP.8.1-neutralizing...

PFE : 25.70 (+0.51%)
BNTX : 96.00 (-0.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

BioNTech SE is a biotechnology company. It develops and commercializes immunotherapies for cancer and other diseases. BioNTech SE is based in Mainz, Germany.

See More

Key Turning Points

3rd Resistance Point 100.06
2nd Resistance Point 99.09
1st Resistance Point 97.54
Last Price 96.00
1st Support Level 95.02
2nd Support Level 94.05
3rd Support Level 92.50

See More

52-Week High 129.27
Fibonacci 61.8% 110.91
Fibonacci 50% 105.24
Fibonacci 38.2% 99.56
Last Price 96.00
52-Week Low 81.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar